TORL BioTherapeutics
TORL BioTherapeutics is a US-based biotechnology company that leads 3 cancer trials in OnCo, testing the antibody-drug conjugates TORL-1-23 (ixotatug vedotin) and TORL-5-700 in non-Hodgkin lymphoma and ovarian cancer.
Overview
TORL BioTherapeutics develops antibody-drug conjugates for cancer, drawing on a research partnership with the Slamon laboratory at UCLA. Its lead programme TORL-1-23 (ixotatug vedotin) targets claudin 6 in solid tumours and is in phase 2 for platinum-resistant ovarian cancer; TORL-5-700 is an earlier-stage ADC. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07439653 (phase 1/2, A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma), NCT06690775 (phase 2, CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.) and NCT07322094 (phase 1/2, CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemothera...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- approved products +18
- modalities +4
- regions +6
- registry trials +30
Pegfilgrastim (Neulasta) is a long-acting form of the growth factor G-CSF, given once per chemotherapy cycle to speed white cell recovery and prevent febrile neutropenia; one dose replaces about eleven daily filgrastim injections. Biosimilars have been sold since 2018 and the Onpro on-body injector delivers it automatically the day after chemotherapy; bone pain is the main side effect.
A microtubule poison discovered in the Pacific yew tree, among the most used chemotherapies in breast, lung, and ovarian cancer.
Carboplatin is a platinum chemotherapy that crosslinks DNA; it is part of the standard pre-surgery regimen for triple-negative breast cancer.
Similar pages
not linked directly; found by shared links- TrialStudy to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- CancerAdult granulosa cell tumour of the ovary
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialA Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialStudy of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialOregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- CancerClear cell ovarian cancer
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialOregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialPhase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.